IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Pulmonary Metastases
National Cancer Institute (NCI)protein_peptidePhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Pulmonary Metastases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
su011248 Association of Urologic Oncology (AUO) | Phase 2 | CCC |
5-azacytidine National Cancer Institute (NCI) | Phase 1/2 | CC |
Ipilimumab Masonic Cancer Center, University of Minnesota | Phase 1/2 | CC |
Carboplatin Sun Yat-sen University | N/A | D |
Irinotecan Sun Yat-sen University | N/A | D |
(+)-VINCRISTINE Sun Yat-sen University | N/A | D |
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →